Campadelli-Fiume G - Search Results

1

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL. Nanni P, et al. PLoS Pathog. 2013 Jan;9(1):e1003155. doi: 10.1371/journal.ppat.1003155. Epub 2013 Jan 31. PLoS Pathog. 2013. PMID: 23382683 Free PMC article.

2

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.

Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G. Menotti L, et al. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9039-44. doi: 10.1073/pnas.0812268106. Epub 2009 May 20. Proc Natl Acad Sci U S A. 2009. PMID: 19458262 Free PMC article.

3

Rethinking herpes simplex virus: the way to oncolytic agents.

Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Campadelli-Fiume G, et al. Rev Med Virol. 2011 Jul;21(4):213-26. doi: 10.1002/rmv.691. Epub 2011 May 27. Rev Med Virol. 2011. PMID: 21626603 Review.

4

The molecular basis of herpesviruses as oncolytic agents.

Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C. Menotti L, et al. Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. doi: 10.2174/138920112800958931. Curr Pharm Biotechnol. 2012. PMID: 21740356 Review.

5

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.

Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini PL, Campadelli-Fiume G. Leoni V, et al. Oncotarget. 2015 Oct 27;6(33):34774-87. doi: 10.18632/oncotarget.5793. Oncotarget. 2015. PMID: 26430966 Free PMC article.

6

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G. Leoni V, et al. PLoS Pathog. 2018 Aug 6;14(8):e1007209. doi: 10.1371/journal.ppat.1007209. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30080893 Free PMC article.

7

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.

Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G. Menotti L, et al. Viruses. 2018 Jun 30;10(7):352. doi: 10.3390/v10070352. Viruses. 2018. PMID: 29966356 Free PMC article.

8

Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.

Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G. Menotti L, et al. J Virol. 2008 Oct;82(20):10153-61. doi: 10.1128/JVI.01133-08. Epub 2008 Aug 6. J Virol. 2008. PMID: 18684832 Free PMC article.

9

Oncolytic herpes virus retargeted to HER-2.

Lollini PL, Menotti L, De Giovanni C, Campadelli-Fiume G, Nanni P. Lollini PL, et al. Cell Cycle. 2009 Sep 15;8(18):2859-60. doi: 10.4161/cc.8.18.9368. Epub 2009 Sep 26. Cell Cycle. 2009. PMID: 19729994 No abstract available.

10

Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.

Gambini E, Reisoli E, Appolloni I, Gatta V, Campadelli-Fiume G, Menotti L, Malatesta P. Gambini E, et al. Mol Ther. 2012 May;20(5):994-1001. doi: 10.1038/mt.2012.22. Epub 2012 Feb 21. Mol Ther. 2012. PMID: 22354378 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters